Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial

Idorn Thomas; Knop Filip K.; Jorgensen Morten B.; Jensen Tonny; Resuli Marsela; Hansen Pernille M.; Christensen Karl B.; Holst Jens J.; Hornum Mads; Feldt-Rasmussen Bo

首页> 外文期刊>Diabetes care >Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial

【24h】

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial

机译：利拉鲁肽在2型糖尿病和终末期肾脏疾病患者中的安全性和有效性：研究者发起，安慰剂对照，双盲，平行分组，随机试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVE To evaluate parameters related to safety and efficacy of liraglutide in patients with type 2 diabetes and dialysis-dependent end-stage renal disease (ESRD).

机译：目的评估与利拉鲁肽在2型糖尿病和透析相关性终末期肾病（ESRD）患者中的安全性和有效性相关的参数。

著录项

来源
《Diabetes care》 |2016年第2期|共8页
作者
Idorn Thomas; Knop Filip K.; Jorgensen Morten B.; Jensen Tonny; Resuli Marsela; Hansen Pernille M.; Christensen Karl B.; Holst Jens J.; Hornum Mads; Feldt-Rasmussen Bo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial [J] . Idorn Thomas, Knop Filip K., Jorgensen Morten B., Diabetes care . 2016,第2期

机译：利拉鲁肽在2型糖尿病和终末期肾脏疾病患者中的安全性和有效性：研究者发起，安慰剂对照，双盲，平行分组，随机试验
2. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study [J] . Kashiwagi A., Takahashi H., Ishikawa H., Diabetes, obesity & metabolism . 2015,第2期

机译：一项关于伊格列净治疗2型糖尿病和肾功能不全患者的长期疗效和安全性的随机，双盲，安慰剂对照研究：对患有肾功能不全的2型糖尿病患者进行长期ASP1941安全性评估的结果（LANTERN）研究
3. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial [J] . Sorli Christopher, Harashima Shin-ichi, Tsoukas George M., The lancet. Diabetes & endocrinology. . 2017,第4期

机译：患有2型糖尿病患者的一次每周半蛋白质单药治疗的疗效和安全性（持续1）：双盲，随机，安慰剂控制，平行群，跨国，多元相3A试验
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective randomised placebo-controlled double-blinded parallel intervention study [O] . Thomas Idorn, Filip K Knop, Morten Jørgensen, 2013

机译：利拉鲁肽在2型糖尿病和终末期肾病患者中的安全性和有效性：研究人员启动的前瞻性随机安慰剂对照双盲平行干预研究的方案
7. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blinded, Parallel Group, Randomized Trial [O] . Thomas Idorn, Filip K. Knop, Morten B. Jørgensen, 2015

机译：Liraglutide在2型糖尿病和末期肾病患者中的安全性和有效性：调查员启动，安慰剂控制，双盲，平行组，随机试验

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial

摘要

著录项

相似文献

相关主题

期刊订阅